Using dCas9-VPR (VP64-p65-Rta), PTEN expression can be reactivated in melanoma cell lines, resulting in the repression of AKT, mTOR, and MAPK oncogenic pathways and increased sensitivity to B-Raf and P13K/mTOR inhibitors [197]. The gene discussed is PTEN; the disease is melanoma.